2009-02-25
Surveillance of bladder cancer
Publication
Publication
The urinary bladder together with the pyelum, ureters and urethra form the urinary tract system (figure 1.1); the system that is responsible for the excretion and collection of urine. With approximately 357,000 new cases per year worldwide, tumours of the urinary tract system contribute significantly to the overall human cancer burden1. Urothelial cancer of the bladder is the fifth most common malignancy in the western world and accounts for 5% of all diagnosed cancers2. In Japan a much lower incidence is seen (Figure 1.2a). In the Netherlands, approximately 4,550 new cases present each year (Figure 1.2b), one of the highest incidence rates in the European Union.
| Additional Metadata | |
|---|---|
| , | |
| The research was funded by ZON-MW (The Netherlands Organization for Health Research and Development), grant number 945-02-046, and the Erasmus MC Rotterdam. Financial support for the printing of this thesis was obtained by kind contributions from: J.E. Jurriaanse Stichting, Astellas, AstraZeneca, Abbott, GlaxoSmithKline, Mathot, Nycomed, Novartis, Pfizer, Pohl Boskamp, Sanofi Aventis and Wyeth Pharmaceuticals | |
| Th.H. van der Kwast (Theo) , E.W. Steyerberg (Ewout) , E.C. Zwarthoff (Ellen) | |
| Erasmus University Rotterdam | |
| hdl.handle.net/1765/38095 | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
van der Aa, M. (2009, February 25). Surveillance of bladder cancer. Retrieved from http://hdl.handle.net/1765/38095 |
|
